Key facts
- It has raised $5.8M; the latest was Early Stage VC ($5.8M) in Dec 2025.
- Notable investors include Bayern Kapital, b2venture, Becker Ventures, Matterwave Ventures, xista science ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Amplifold
- ·The full record, as it builds
Funding rounds
No funding rounds for Amplifold are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amplifold
Developer of diagnostic test technology designed for highly sensitive detection in lateral flow assays. The company's platform uses DNA-origami nanotechnology to deliver multiple sensitivities at similar production costs, integrates into existing manufacturing workflows, enabling the diagnostics market to enhance test performance without major redevelopment.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2025
- Employees
- 5
- Website
- amplifold.com/
- Ownership
- Privately Held (backing)
Amplifold doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amplifold shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amplifold in its N-PORT filings yet. We sweep new filings monthly.